Pandora A/S
Reduction of Pandora A/S’ share capital
Reduction of Pandora A/S’ share capital
At Pandora A/S’ Annual General Meeting on 12 March 2025, it was resolved to reduce the
Company’s share capital with a nominal amount of DKK 3,000,000 by cancellation of 3,000,000 treasury shares of DKK 1.
The share capital reduction was announced in the Danish Business Authority's it-system on 12 March 2025 and the 4-week notification period has expired with no objections.
The Board of Directors has therefore resolved to effect the share capital reduction. After reduction of the share capital, the Company’s share capital is nominally DKK 79,000,000, divided into shares of DKK 1.
ABOUT PANDORA
Pandora is the world's largest jewellery brand, specialising in the design, crafting and marketing of accessible luxury jewellery made from high-quality materials. Each piece is created to inspire self-expression, allowing people to share their stories and passions through meaningful jewellery. Pandora jewellery is sold in more than 100 countries through 6,800 points of sale, including more than 2,700 concept stores.
Headquartered in Copenhagen, Denmark, Pandora employs 37,000 people worldwide and crafts its jewellery using only recycled silver and gold. Pandora is committed to leadership in sustainability and has set out to halve greenhouse gas emissions across its value chain by 2030. Pandora is listed on the Nasdaq Copenhagen stock exchange and generated revenue of DKK 31.7 billion (EUR 4.2 billion) in 2024.
CONTACT
For more information, please contact:
Investor Relations BILAL AZIZ SVP, Investor Relations & Treasury +45 3137 9486 biazi@pandora.net | Corporate Communications JOHAN MELCHIOR VP, Media Relations & Public Affairs +45 4060 1415 jome@pandora.net |
ADAM FUGLSANG Director, Investor Relations +45 6167 7425 adfug@pandora.net |
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Idorsia Pharmaceuticals Ltd30.4.2025 07:00:00 CEST | Press release
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
Hiab Corporation30.4.2025 07:00:00 CEST | Press release
Hiab's interim report January–March 2025: Profitability improved driven by strong execution in all divisions
Ress Life Investments A/S30.4.2025 07:00:00 CEST | Press release
Ress Life Investments A/S to divest most of its current life insurance portfolio
Augustine Therapeutics30.4.2025 07:00:00 CEST | Press release
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO
F. Hoffmann-La Roche Ltd30.4.2025 07:00:00 CEST | Press release
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom